Approval · Notice of Compliance 12297 · 2011
EBIXA: Notice of Compliance 12297
Issued April 21, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12297
- Date
- April 21, 2011
- Company
- Lundbeck Canada IncSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of commitments as per the Letter of Undertaking dated October 14, 2004 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer's type
- Therapeutic class
- N-methyl-D-aspartate (NMDA) receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EBIXA | Not yet assigned | — |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 10 MG per TAB